Skip to content
Screener

Serina Therapeutics SER Q3 2026 earnings

Reported November 12, 2026 · After market close

Revenue$125.0KIn line
EPS-$0.31Beat by $0.03
Revenue estimate$125.0K
EPS estimate-$0.34
“We are excited about the achievement of important clinical milestones for SER-252 in Parkinson's disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation. Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development. Dosing in Cohort 2 is currently underway and focuses on demonstrating SER-252's potential as a differentiated treatment option for patients with advanced Parkinson's disease to improve the significant challenge of consistent symptom control.”
Steve Ledger

Next report

Date not yet announced

FAQ

When did Serina Therapeutics report Q3 2026 earnings?
Serina Therapeutics (SER) reported Q3 2026 earnings on November 12, 2026 after market close.
What were Serina Therapeutics's Q3 2026 revenue and EPS?
Serina Therapeutics reported revenue of $125.0K and eps of $-0.31 for Q3 2026.
Did Serina Therapeutics beat estimates in Q3 2026?
Revenue beat the consensus estimate of $125.0K by -. EPS beat the consensus estimate of $-0.34 by $0.03.
How did Serina Therapeutics's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 31.1% from $-0.45.
Where can I find Serina Therapeutics's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001708599-26-000069) and the 10-Q periodic report (0001708599-26-000068) directly on SEC EDGAR. The filing index links above go to sec.gov.